Item 2.02. Results of Operations and Financial Condition.
On August 5, 2020, Bellerophon Therapeutics, Inc. issued a press release
announcing its financial and operational results for the three and six months
ended June 30, 2020. The full text of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and
not filed:
99.1 Press Release dated August 5, 2020.
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses